As the Generics Bulletin reports, half of Canada’s provinces have now announced biosimilar switching policies.
Who we are
Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.
Learn more about biosimilars and their benefits for patients and healthcare systems.
Report from the AJMC Center for Biosimilars on Nova Scotia’s new biosimilar switching initiative.
CBC News coverage of the announcement of Nova Scotia’s biosimilar switching policy, which is expected to save the province more than $13 million annually.